ERBB2 and breast cancer: In addition, we observed in “ER-low” tumours a distribution of HER2 status resembling that of ER-negative breast cancer, thus adding another line of evidence on the ambiguous nature of “ER-low” breast cancer that likely represents ER-negativity based on molecular and clinical data [23–26].